Garenoxacin

Summary

Garenoxacin (CHEMBL215303) is an approved small-molecule antibacterial drug (ATC J01MA19); indicated across 1 condition including bacterial infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01MA19
• Indications: 1 condition
• Chemistry: 426.4 Da · C23H20F2N2O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL215303
Name	Garenoxacin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	124093
ChEBI	CHEBI:131716
ATC	J01MA19
Molecular formula	C23H20F2N2O4
Molecular weight	426.4
InChIKey	NJDRXTDGYFKORP-LLVKDONJSA-N

SMILES: C[C@@H]1C2=C(CN1)C=C(C=C2)C3=C(C4=C(C=C3)C(=O)C(=CN4C5CC5)C(=O)O)OC(F)F

IUPAC name: 1-cyclopropyl-8-(difluoromethoxy)-7-[(1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl]-4-oxoquinoline-3-carboxylic acid

ChEBI definition: A quinolinemonocarboxylic acid that is 1,4-dihydroquinoline-3-carboxylic acid that is substituted by a cyclopropyl group at position 1, an oxo group at position 4, a (1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl group at position 7, and a difluoromethoxy group at position 8.

Pharmacological roles (ChEBI): antibacterial drug, non-steroidal anti-inflammatory drug.

Also known as: Garenoxacin, Garenoxacine, Garenoxacino, T-3811, garenoxacin, SID50126319, GARENOXACIN, Enoxacine, Garenoxacin (Mesylate hydrate)

Parent form; salt/anhydrous children: CHEMBL3183451

Patent coverage: 247 distinct patent families (524 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 475 (91%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	2	MONDO:0005113	EFO:0000771

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).